Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDO-4033
- Development stage
- Unknown
- Lead developer
- China Pharmaceutical University
- Modality
- Small Molecules
01
Overview
DDO-4033: sourced facts only. name: "Here, we identified DDO-4033 as a potent SPOP inhibitor through virtual screening and optimization." [PMID:40622869]; target: "Here, we identified DDO-4033 as a potent SPOP inhibitor through virtual screening and optimization." [PMID:40622869]; developer: "Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China." [PMID:40622869]; modality: "This 2-pyrazolylpyrimidinone derivative exhibited potent affinity with SPOP in vitro and efficiently impeded the malignant migration, invasion, and proliferation of ccRCC cell lines." [PMID:40622869]
02
Targets
E3 ligase (E3 ubiquitin ligases)
Beyond the preview
Go deeper on DDO-4033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDO-4033.